Institution
Lenox Hill Hospital
Healthcare•New York, New York, United States•
About: Lenox Hill Hospital is a healthcare organization based out in New York, New York, United States. It is known for research contribution in the topics: Population & Stent. The organization has 2569 authors who have published 3561 publications receiving 114326 citations.
Topics: Population, Stent, Arthroplasty, Angioplasty, Myocardial infarction
Papers published on a yearly basis
Papers
More filters
••
TL;DR: These results are an improvement compared with historical controls using bare metal stents in coronary bifurcation lesions, but restenosis at the SB remains a problem.
Abstract: Background— A sirolimus-eluting stent (Cypher, Cordis Corp) has been reported to markedly decrease restenosis in selected lesions; higher-risk lesions, including coronary bifurcations, have not been studied. Methods and Results— This prospective study evaluated the safety and efficacy of sirolimus-eluting stents for treatment of coronary bifurcation lesions. Patients were randomly assigned to either stenting of both branches (group A) or stenting of the main branch with provisional stenting of the side branch (SB) (group B). Eighty-five patients (86 lesions) were enrolled. There was 1 case of unsuccessful delivery of any device at the bifurcation site. Given the high crossover, more lesions were treated with 2 stents (n=63) than with stent/balloon (n=22). Clinical follow-up at 6 months was completed in all patients and angiographic follow-up in 53 patients in group A (85.5%) and 21 in group B (95.4%). One patient died suddenly 4.5 months after the procedure. There were 3 cases of stent thrombosis (3.5%). ...
782 citations
••
TL;DR: Implantation of the PHV can be achieved in patients with end-stage calcific aortic stenosis and might become an important therapeutic option for patients not amenable to surgical valve replacement.
731 citations
••
University of Barcelona1, Nihon University2, Taipei Veterans General Hospital3, Kindai University4, Peking Union Medical College5, Queen Mary University of London6, Kyungpook National University7, Asan Medical Center8, Tianjin Medical University9, Lenox Hill Hospital10, University of Bologna11, University of Tokyo12, Bayer HealthCare Pharmaceuticals13, Mount Sinai Hospital14
TL;DR: The data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation.
Abstract: Summary Background There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy and safety of sorafenib versus placebo as adjuvant therapy in patients with hepatocellular carcinoma after surgical resection or local ablation. Methods We undertook this phase 3, double-blind, placebo-controlled study of patients with hepatocellular carcinoma with a complete radiological response after surgical resection (n=900) or local ablation (n=214) in 202 sites (hospitals and research centres) in 28 countries. Patients were randomly assigned (1:1) to receive 400 mg oral sorafenib or placebo twice a day, for a maximum of 4 years, according to a block randomisation scheme (block size of four) using an interactive voice-response system. Patients were stratified by curative treatment, geography, Child-Pugh status, and recurrence risk. The primary outcome was recurrence-free survival assessed after database cut-off on Nov 29, 2013. We analysed efficacy in the intention-to-treat population and safety in randomly assigned patients receiving at least one study dose. The final analysis is reported. This study is registered with ClinicalTrials.gov, number NCT00692770. Findings We screened 1602 patients between Aug 15, 2008, and Nov 17, 2010, and randomly assigned 1114 patients. Of 556 patients in the sorafenib group, 553 (>99%) received the study treatment and 471 (85%) terminated treatment. Of 558 patients in the placebo group, 554 (99%) received the study treatment and 447 (80%) terminated treatment. Median duration of treatment and mean daily dose were 12·5 months (IQR 2·6–35·8) and 577 mg per day (SD 212·8) for sorafenib, compared with 22·2 months (8·1–38·8) and 778·0 mg per day (79·8) for placebo. Dose modification was reported for 497 (89%) of 559 patients in the sorafenib group and 206 (38%) of 548 patients in the placebo group. At final analysis, 464 recurrence-free survival events had occurred (270 in the placebo group and 194 in the sorafenib group). Median follow-up for recurrence-free survival was 8·5 months (IQR 2·9–19·5) in the sorafenib group and 8·4 months (2·9–19·8) in the placebo group. We noted no difference in median recurrence-free survival between the two groups (33·3 months in the sorafenib group vs 33·7 months in the placebo group; hazard ratio [HR] 0·940; 95% CI 0·780–1·134; one-sided p=0·26). The most common grade 3 or 4 adverse events were hand-foot skin reaction (154 [28%] of 559 patients in the sorafenib group vs four [ vs five [ Interpretation Our data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation. Funding Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals.
721 citations
••
TL;DR: The data, showing a low incidence of toxicity in 396 patients, coupled with the previously demonstrated efficacy of 6-mercaptopurine in the treatment ofinflammatory bowel disease, indicate that the drug is a reasonable alternative in the management of patients with intractable inflammatory bowel disease.
Abstract: We assess toxicity related to 6-mercaptopurine in the treatment of inflammatory bowel disease by reporting our experience with 396 patients (120 patients with ulcerative colitis, 276 with Crohn disease) observed over 18 years. Follow-up data for a mean period of 60.3 months were obtained for 90% of the patients. Toxicity directly induced by 6-mercaptopurine included pancreatitis in 13 patients (3.3%), bone marrow depression in 8 (2%), allergic reactions in 8 (2%), and drug hepatitis in 1 (0.3%). These complications were reversible in all cases with no mortality. Most cases of marrow depression occurred earlier in our experience, when the initial drug doses used were higher. Infectious complications were seen in 29 patients (7.4%), of which 7 (1.8%) were severe, including one instance of herpes zoster encephalitis. All infections were reversible with no deaths. Twelve neoplasms (3.1%) were observed, but only 1 (0.3%), a diffuse histiocytic lymphoma of the brain, had a probable association with the use of 6-mercaptopurine. Our data, showing a low incidence of toxicity in 396 patients, coupled with the previously demonstrated efficacy of 6-mercaptopurine in the treatment of inflammatory bowel disease, indicate that the drug is a reasonable alternative in the management of patients with intractable inflammatory bowel disease.
710 citations
••
Cleveland Clinic1, Columbia University Medical Center2, Cedars-Sinai Medical Center3, St. Paul's Hospital4, Scott & White Hospital5, Duke University6, Emory University7, University of Pennsylvania8, MedStar Washington Hospital Center9, New York University10, Lenox Hill Hospital11, Stanford University12, Brigham and Women's Hospital13
TL;DR: TAVR should be strongly considered for patients who are not surgical candidates for aortic valve replacement to improve their survival and functional status, and Appropriate selection of patients will help to maximise the benefit of TAVR and reduce mortality from severe comorbidities.
707 citations
Authors
Showing all 2596 results
Name | H-index | Papers | Citations |
---|---|---|---|
Martin B. Leon | 163 | 1400 | 129393 |
Richard B. Devereux | 144 | 962 | 116403 |
Roxana Mehran | 141 | 1378 | 99398 |
Kenneth Offit | 122 | 576 | 46548 |
Alexandra J. Lansky | 114 | 632 | 54445 |
Joshua J. Jacobs | 107 | 455 | 34463 |
George Dangas | 102 | 773 | 41137 |
Jeffrey W. Moses | 100 | 571 | 58868 |
Michael J. Pencina | 100 | 419 | 55000 |
Roberto M. Lang | 96 | 823 | 56638 |
Scott C. Weaver | 92 | 536 | 32230 |
Michael A. Mont | 86 | 1072 | 32026 |
Michael R. Jaff | 82 | 442 | 28891 |
Stephen J. Meltzer | 82 | 276 | 24789 |
Jack Wang | 79 | 211 | 18756 |